Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research
Sponsored by Peking University First Hospital
About this trial
Last updated 13 years ago
Study ID
LEADER
Status
Unknown
Type
Observational
Placebo
No
Accepting
45+ Years
All Sexes
Trial Timing
Ended 11 years ago
What is this trial about?
The purpose of this study is to determine whether the effectiveness of levamlodipine maleate (xuanning) is noninferior to amlodipine besylate (Norvasc) in treatment of hypertension in a Chinese primary hypertension population.
What are the participation requirements?
Inclusion Criteria
* systolic pressure ≥140mmHg or diastolic pressure ≥90mmHg or receiving antihypertensive drug treatment
* Patient himself/herself or his/her family member has already signed the informed consent form
* Patient is fit for use of Levamlodipine Maleate or amlodipine besylate
* Age≥45
Exclusion Criteria
* patient with secondary hypertension
* patients who has suffered from myocardial infarction or stroke within the latest 3 months
* patients who has obvious intelligence、hearing and limb's activity disability
* Patients with severe disease, with a life expectancy of less than two years